Vascular Closure Devices Market Set for Steady Expansion by 2032, Driven by Innovation and Growing Surgical Volumes | DelveInsight

The vascular closure devices market was valued at USD 1.05 billion in 2023 and is projected to grow at a CAGR of 6.15%, reaching approximately USD 1.49 billion by 2030. This growth is largely driven by the rising prevalence of chronic conditions, particularly cardiovascular diseases such as atrial fibrillation and coronary artery disease (CAD). Additionally, the increasing preference for minimally invasive procedures and ongoing product innovations by key industry players are expected to further fuel demand for vascular closure devices throughout the forecast period from 2024 to 2030.

DelveInsight's Vascular Closure Devices Market Insights report provides the current and forecast market analysis, individual leading Vascular Closure Devices companies' market shares, challenges, Vascular Closure Devices market drivers, barriers, and trends, and key Vascular Closure Devices companies in the market.

Request for a detailed sample report @ https://www.delveinsight.com/report-store/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Vascular Closure Devices Market Report

The Vascular Closure Devices market is projected to grow at a moderate CAGR from 2025 to 2032.
As per DelveInsight estimates, North America is anticipated to dominate the global Vascular Closure Devices market during the forecast period.
Several major companies actively participating in the vascular closure devices market include Abbott, Teleflex Incorporated, Terumo Medical Corporation, Cardinal Health, Cardival Medical, Inc., Merit Medical Systems, Medtronic, Morris Innovative, TZ Medical, Vasorum Ltd, Tricol Biomedical, Vivasure Medical Ltd, Transluminal Technologies, W. L. Gore & Associates, Inc., Meril Life Sciences Pvt. Ltd, Gem srl, among others.
In September 2024, Cordis received FDA approval for its MYNX Control venous vascular closure device (VCD), intended for access sites ranging from 6 to 12 French. The device incorporates Grip Technology and a hydrophilic polyethylene glycol (PEG) sealant, which reportedly absorbs three times faster than collagen-based alternatives, promoting quicker hemostasis.
In August 2024, Haemonetics announced the nationwide launch of its Vascade MVP XL mid-bore venous closure system in the U.S. Part of the Vascade product line, this device features an enhanced collagen component and a larger disc, making it suitable for 10-12F sheaths used in procedures such as cryoablation and left atrial appendage closure.
Earlier, in July 2024, Cordis gained FDA approval for the MYNX Control VCD targeting 6-12F access sites, with plans to introduce it to the market shortly thereafter.
In June 2024, Haemonetics initiated a limited release of the VASCADE MVP XL system, which incorporates a collapsible disc and a resorbable collagen patch to support faster hemostasis.
On April 16, 2024, Vivasure Medical reported the successful treatment of its first large-bore venous patient using the PerQseal Elite vascular closure system-a fully absorbable, suture-free device. This procedure was conducted as part of the ELITE Venous Clinical Study led by Prof. Nicolas Van Mieghem at Erasmus Medical Centre in Rotterdam.

To read more about the latest highlights related to the Vascular Closure Devices market, get a snapshot of the key highlights entailed in the Global Vascular Closure Devices Market Report https://www.delveinsight.com/sample-request/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Vascular Closure Devices Overview

Vascular closure devices (VCDs) are medical tools used to achieve hemostasis by sealing puncture sites in arteries or veins following catheterization procedures, such as angiography, angioplasty, or other interventional cardiovascular treatments. These devices are designed to close the access site quickly and effectively, helping to reduce complications such as bleeding, hematoma, and prolonged bed rest.

Vascular Closure Devices Market Insights

North America is projected to lead the vascular closure devices market in 2023 and maintain its dominance throughout the forecast period. This growth is largely driven by the high incidence of cardiovascular conditions such as coronary artery disease (CAD) and myocardial infarctions, along with widespread risk factors like hypertension, high cholesterol, and smoking. Additionally, continuous innovation in device development and increased regulatory approvals are anticipated to further fuel market expansion from 2024 to 2030.

According to data from the National Institutes of Health (2023), approximately 20.5 million people in the United States were living with CAD. Furthermore, the Centers for Disease Control and Prevention (CDC) reported in 2024 that an estimated 805,000 Americans experience a myocardial infarction (heart attack) each year. The CDC also noted that heart disease is a broad category that includes conditions such as acute coronary syndrome, atherosclerosis, and congestive heart failure. Key contributing risk factors include high blood pressure, elevated cholesterol levels, and smoking-affecting nearly 47% of the U.S. population with at least one of these three conditions.

To know more about why North America is leading the market growth in the Vascular Closure Devices market, get a snapshot of the Vascular Closure Devices Market Outlook https://www.delveinsight.com/report-store/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Vascular Closure Devices Market Dynamics

According to the World Heart Report (2023), over 500 million people worldwide were living with cardiovascular diseases as of 2021. Additionally, data from the American Heart Association (2023) projects that by 2030, more than 12 million people globally will be affected by atrial fibrillation.

The British Heart Foundation's *Global Heart & Circulatory Diseases Factsheet* (2024) also reported that approximately 200 million individuals around the world are living with coronary artery disease (CAD). Vascular closure devices play a vital role in safely sealing access sites following diagnostic and therapeutic procedures such as angiography, angioplasty, and stent placements. In the context of atrial fibrillation, these devices support the secure closure of access points after catheter-based treatments, helping to reduce complications and accelerate recovery. Similarly, in CAD interventions, vascular closure devices are essential in minimizing bleeding risks at the catheter insertion site and improving overall procedural outcomes.

Vascular Closure Devices Market Drivers:
Increasing cases of chronic disorders such as cardiovascular diseases including atrial fibrillation and coronary artery disease (CAD) with the rising shift towards minimally invasive approaches
Innovative product developmental activities by leading companies


Get a sneak peek at the Vascular Closure Devices market dynamics @ https://www.delveinsight.com/sample-request/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Coverage: Global
Study Period: 2022 to 2032
Key Vascular Closure Devices Companies: Abbott, Teleflex Incorporated, Terumo Medical Corporation, Cardinal Health, Cardival Medical, Inc., Merit Medical Systems, Medtronic, Morris Innovative, TZ Medical, Vasorum Ltd, Tricol Biomedical, Vivasure Medical Ltd, Transluminal Technologies, W. L. Gore & Associates, Inc., Meril Life Sciences Pvt. Ltd, Gem srl, and others.

Which MedTech key players in the Vascular Closure Devices market are set to emerge as the trendsetter, explore @ Vascular Closure Devices Companies https://www.delveinsight.com/report-store/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Table of Contents
1. Vascular Closure Devices Market Report Introduction
2. Vascular Closure Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Vascular Closure Devices Market Key Factors Analysis
6. Vascular Closure Devices Market Porter's Five Forces Analysis
7. Vascular Closure Devices Market Layout
8. Vascular Closure Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.